Enoxaparin injection should not be administered by IM route. Enoxaparin should be used with caution in conditions with increased potential for bleeding eg, impaired hemostasis, history of peptic ulcer, recent ischemic stroke, uncontrolled severe arterial hypertension, diabetic retinopathy, recent neuro or ophthalmologic surgery and low weight patients. It is recommended that the platelet count should be measured before the initiation of the treatment and regularly thereafter during treatment.
Use in pregnancy: Pregnancy Category B: In humans, there is no evidence that enoxaparin crosses the placental barrier. Enoxaparin should be used during pregnancy only if the physician has established a clear need. Enoxaparin is not recommended for use in pregnant women with prosthetic heart valves.
Use in lactation: It is not known whether this drug is excreted in human milk. However, as a precaution, lactating mothers receiving enoxaparin sodium should be advised to avoid breastfeeding.
Use in children: The safety and efficacy of enoxaparin sodium in children have not been established.
Use in the elderly: No dose reduction is necessary in the elderly, unless kidney function is impaired.